Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01396304
Other study ID # 4835-W
Secondary ID
Status Terminated
Phase Phase 4
First received July 14, 2011
Last updated February 12, 2013
Start date October 2011
Est. completion date February 2013

Study information

Verified date February 2013
Source Hollister Wound Care LLC
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

Calcium alginate dressings with silver have been found to be safe and effective for use for leg ulcers. The primary objective is to compare Restore Calcium Alginate Dressing, Silver to AqualCel Ag Dressing on the following parameters: No further progression toward infection (bioburden), ease of application and removal, and percent progression to closure. The secondary objective is to obtain photographic documentation of the leg ulcers during the course of the study.


Recruitment information / eligibility

Status Terminated
Enrollment 19
Est. completion date February 2013
Est. primary completion date February 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Is 18 years or older; male or female.

2. Previous diagnosis of venous insufficiency proven by a positive venous duplex with reflux.

3. Has a venous ulcer with a wound area between 5 cm2 - 40 cm2.

4. Has an ankle brachial index (ABI) >0.8.

5. Has a venous ulcer with duration less than 24 months.

6. Has a venous ulcer which is critically colonized (not infected) based on the Lazareth Study Model. Ulcers are considered to be critically colonized if at least three of the five following signs are present:

Severe spontaneous pain between two dressing changes,Perilesional erythema,Local edema,Malodour,Heavy Exudation

7. Is currently using Profore as their standard of care.

8. Has not received antibiotics for 6 weeks prior to enrollment.

Exclusion Criteria

1. Has an allergy to one of the components of the dressings (calcium alginate, hydrocolloid [carboxymethylceullose], silver).

2. Is currently on antibiotics.

3. Has a negative venous duplex.

4. Is unable to tolerate 4 layer compression.

5. Is unable to continue contact with the investigator for a period of at least two weeks.

6. Is unwilling or unable to comply with the study protocol.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Device:
Restore Calcium Alginate Dressing
Wound dressing appropriate for venous leg ulcers. Dressing to be changed minimally once per week.
AquaCel Ag Wound Dressing
Wound dressing appropriate for venous leg ulcers. Dressing to be changed minimally once per week.

Locations

Country Name City State
United States Lake Washington Vascular Surgeons Bellevue Washington
United States Wound Institute & Research Center Dunmore Pennsylvania
United States Bayshore Community Hospital Holmdel New Jersey
United States LSU Health Sciences Center Shreveport Louisiana
United States Palms of Pasadena Hospital St. Petersburg Florida

Sponsors (1)

Lead Sponsor Collaborator
Hollister Wound Care LLC

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary The primary objective is to compare Restore Calcium Alginate Dressing, Silver to AqualCel Ag Dressing on the following parameters: No further progression toward infection (bioburden), ease of application and removal, and percent progression to closure. Observations will be collected over 6 weeks for a total of 7 visits No
Secondary The secondary objective is to obtain photographic documentation of the venous leg ulcers during the course of the study. Observations will be collected over 6 weeks in a total of 7 visits. No
See also
  Status Clinical Trial Phase
Completed NCT04529421 - Assocation Between In-person Instruction and COVID-19 Risk
Recruiting NCT04081792 - Optimal Antibiotics for Operated Diabetic Foot Infections N/A
Completed NCT04332861 - Evaluation of Infection in Obstructing Urolithiasis
Recruiting NCT04674657 - Does Extra-Corporeal Membrane Oxygenation Alter Antiinfectives Therapy Pharmacokinetics in Critically Ill Patients
Enrolling by invitation NCT05052203 - Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
Recruiting NCT00342589 - New Techniques for Using a Saline Wash as a Diagnostic Tool for Pneumocystis Pneumonia
Completed NCT03295825 - Heparin Binding Protein in Early Sepsis Diagnosis N/A
Completed NCT03296423 - Bacillus Calmette-guérin Vaccination to Prevent Infections of the Elderly Phase 4
Withdrawn NCT04217252 - Clinical Application of High-throughput Sequencing Technology for the Diagnosis of Patients With Severe Infection N/A
Recruiting NCT02899143 - Short-course Antimicrobial Therapy in Sepsis Phase 2
Recruiting NCT02905552 - Myelodysplasic Syndromes and Risk Factors for Infection N/A
Withdrawn NCT02904434 - Gastrointestinal Implications of Voriconazole Exposure
Active, not recruiting NCT02768454 - Antimicrobials Stewardship by Pharmacist N/A
Completed NCT02219776 - Decreasing Infection In Arthroscopic Shoulder Surgery N/A
Completed NCT02210169 - RCT of Continuous Versus Intermittent Infusion of Vancomycin in Neonates N/A
Recruiting NCT02098226 - Evaluation of MALDI Biotyper CA System for Detection of Gram- and Gram+ Bacteria and Yeasts N/A
Completed NCT01846832 - A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection Phase 3
Terminated NCT01441206 - Safety and Pharmacokinetics of Single and Multiple Dose Rifampin in Infants Phase 1
Completed NCT01434797 - Value of PET/CT Imaging in the Diagnosis of Permanent Central Venous Catheters Infection
Completed NCT01159834 - Human Papillomavirus (HPV) Vaccination in Barretos (Pio XII Foundation - Barretos Cancer Hospital) N/A